Table 1.

Effect of age on the risk of second primary cancers in renal cell carcinoma

Site of second malignancy	Age at diagnosis of RCC			Age attained at diagnosis of second primary cancer
	0–29 yrs.	30–59 yrs.	≥60 yrs.	0–29 yrs.	30–59 yrs.	≥60 yrs.
	O(SIR)	O(SIR)	O(SIR)	O(SIR)	O(SIR)	O(SIR)
All sites	23 (6.6)*	1,232 (1.3)*	2,540 (1.13)*	5 (12.02)*	574 (1.72)*	3,216 (1.12)*
All solid tumors	19 (6.4)	1,143 (1.32)	2,258 (1.13)	5 (16.0)	533 (1.78)*	2,882 (1.12)*
All lymphatic and Hematopoietic diseases	3 (7.1)*	72 (1.01)	223 (1.25)*	0 (0)	33 (1.23)	265 (1.2)*
Oral cavity and pharynx	0 (0)	22 (0.8)	32 (0.7)*	0 (0)	14 (1.04)	40 (0.63)* p
Digestive system	0 (0)	200 (1.2)b	518 (1.05)	0 (0)	81 (1.4)* k	637 (1.04) q
Liver, GB IHBD, EHBD, other biliary	0 (0)	22 (1.4)c	35 (0.93)h	0 (0)	12 (2.1)* l	45 (0.94) r
Respiratory system	0 (0)	188 (1.14) d	374 (0.97)	0 (0)	74 (1.42)* m	488 (0.98)
Bones and Joints	0 (0)	1 (1.0)	3 (1.9)	0 (0)	0 (0)	4 (1.9)
Soft tissue including heart	0 (0)	3 90.7)	12 (1.32)	0 (0)	2 (1.0)	13 (1.13)
Skin excluding BCC and SCC	1 (2.9)	43 (1.2)	77 (1.24)	0 (0)	24 (1.42)	97 (1.2)
Breast	1 (1.4)	79 (0.8)	172 (1.05)	0 (0)	45 (0.95)	207 (0.96)
Female Genital system	0 (0)	31 (0.8)	65 (0.98)	0 (0)	16 (0.91)	80 (0.92)
Male Genital system	1 (3.7)	273 (1.2)*e	622 (1.2)*i	0 (0)	81 (1.5)*n	815 (1.17)* s
Urinary bladder	0 (0)	44 (0.9)	198 (1.4)*	0 (0)	15 (1.2)	227 (1.3)*
Kidney	14 (170.0)*	197 (7.6)*	123 (2.7)*	5 (1,101)*	139 (13.6)*	190 (3.1)
Renal pelvis	0 (0)	4 (2.3)	1 (0.2)*	0 (0)	2 (4.2)	3 (0.4)
Ureter	0 (0)	2 (1.8)	8 (2.0)	0 (0)	1 (4.2)	9 (1.8)
Eye and Orbit	0 (0)	3 (2.0)	2 (0.7)	0 (0)	2(3.0)	3 (0.8)
Brain and other Nervous system	0 (0)	14 (1.21)	18 (0.91)	0 (0)	9 (1.7)	23 (0.9)
Endocrine system	2 (8.1)	37 (3.4)*f	31 (2.9)*j	0 (0)	27 (4.3)* o	43 (2.8)* t
Lymphoma	3 (9.9)*a	38 (1.0)	102 (1.2)	0 (0)	18 (1.15)	125 (1.15)
Myeloma	0 (0)	11 (0.95)	39 (1.3)	0 (0)	7 (1.8)	43 (1.1)
Leukemia	0 (0)	23 (1.1)g	82 (1.31)*	0 (0)	8 (1.1)	97 (1.3)*
Mesothelioma	0 (0)	4 (1.7)	7 (0.93)	0 (0)	2 (3.1)	9 (0.97)
Kaposi Sarcoma	1 (10.3)	0 (0)	2(1.3)	0 (0)	1 (0.5)	2 (1.1)
Miscellaneous	0 (0)	15 (0.8)	50 (0.8)	0 (0)	6 (0.98)	59 (0.8)

^*p<0.05, O-observed number of cases; SIR- Standardized incidence ratio (ratio of observed to expected number of second malignancies);

^aSignificant increase in the risk of non-lymphocytic lymphomas (SIR:15.1) specifically for nodal type of NHL (SIR: 23.2);

^bSignificant increase in the risk of an SPC in the hepatic flexure of the colon (SIR: 2.4);

^cSignificant increase in the risk of liver cancer (SIR: 1.9);

^dSignificant increased risk of developing cancer of the lung and bronchus (SIR: 1.2);

^eSignificant increase in the risk of cancer of the prostate (SIR: 1.2);

^fSignificant increase in the risk of thyroid cancer (SIR: 3.5);

^gSignificantly increased risk of developing Acute Monocytic leukemia (SIR: 7.3);

^hSignificant increase in risk of pancreatic cancer (SIR: 1.34);

ⁱSignificant increase in risk of prostate cancer (SIR: 1.2);

^jSignificant increase in the risk of thyroid cancer (SIR: 27) and malignant neoplasms of the adrenal gland (SIR: 7.2);

^kSignificant increase in the risk of SPC in the colon (excluding rectum) (SIR: 1.5);

^lSignificant increase in the risk of an SPC in the liver (SIR: 2.63);

^mSignificant increase in the risk of SPC in the lung and bronchus (SIR: 1.54);

ⁿSignificant increase in risk of prostate cancer (SIR: 1.5);

^oSignificant increase in the risk of SPC in the thyroid gland (SIR: 4.3);

^pSignificant decrease in the risk of an SPC in the pharynx (SIR: 0.4) and hypopharynx (SIR: 0.16);

^qSignificant increase in the risk of SPC in the hepatic flexure of the colon (SIR: 1.66) ;

^rSignificant increase in the risk of pancreatic cancer (SIR: 1.31);

^sSignificant increase in the risk of prostate cancer (SIR: 1.17);

^tSignificant increase in the risk of thyroid cancer (SIR: 2.9) and cancer of the adrenal gland (SIR: 6.6).